TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24672938
Drug: HAART alone
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAART alone (treatment group)
Study: 24672938
Drug: HAART combined
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAART combined with Qiling Decoction (combination group)
Study: 8648209
Drug: Saquinavir (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saquinavir (600 mg, 3 times/day) alone or in combination with zidovudine (200 mg, 3 times/day)
Study: 8648209
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of saquinavir, zidovudine, and dideoxycytidine
Study: 7042029
Drug: Oral metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral metronidazole (n = 46)
Study: 7042029
Drug: Intravenous metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous metronidazole (n = 51)
Study: 25684005
Drug: Remifentanil effect-site
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil effect-site concentration of 1.0 ng/mL (group R1.0)
Study: 25684005
Drug: Remifentanil effect-site
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil effect-site concentration of 1.5 ng/mL (group R1.5)
Study: 25684005
Drug: Remifentanil effect-site
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil effect-site concentration of 0 ng/mL (group R0)
Study: 25684005
Drug: Remifentanil effect-site
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil effect-site concentration of 0.5 ng/mL (group R0.5)
Study: 21836540
Drug: Daclizumab induction
Normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclizumab induction with tacrolimus/mycophenolate combination
Study: 16772244
Drug: Low-fat milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat milk (240 mL, 12 g of lactose)
Study: 9269944
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of benazepril (10 mg) and low-dose amlodipine (2.5 mg)
Study: 3661923
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg fentanyl
Study: 27265743
Drug: Durvalumab or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab or Tremelimumab as monotherapy
Study: 25953222
Drug: Norepinephrine (0.66
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine (0.66 mg/L)
Study: 25953222
Drug: Epinephrine (0.33
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine (0.33 mg/L)
Study: 19478257
Drug: Saccharomyces boulardii
Normalized name: Saccharomyces boulardii
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saccharomyces boulardii (250 mg, twice daily) added to metronidazole
Study: 15573850
Drug: Dexamethasone (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (3 doses of 6 mg IV)
Study: 9129063
Drug: Baseline HIV-1
Normalized name: petrolatum 1 MG/MG [Vaseline]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline HIV-1 RNA level >100,000 copies/mL
Study: 26231850
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with focus on lifestyle (n = 90)
Study: 26231850
Drug: 10-session, 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-session, 1.5 h/week group treatment with focus on parenting (n = 45)
Study: 26231850
Drug: Same group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same group treatment as 2) with additional follow-up sessions (n = 45)
Study: 23601801
Drug: Fluocinolone acetonide
Normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone acetonide (FA) implants
Study: 14710100
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg vaginally administered isosorbide mononitrate
Study: 11268494
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cyclophosphamide (1000 mg/m2 day 1), epidoxorubicin (60 mg/m2 day 1), and vincristine (1.4 mg/m2 day 1) every 14 days for six cycles followed by cisplatin (40 mg/m2 days 1 & 2) and etoposide (100 mg/m2 days 1‐3) every 14 days for four cycles, with prophylactic filgrastim (300 mcg subcutaneously from day 5 to day 10)
Study: 11268494
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cyclophosphamide, epidoxorubicin, and vincristine followed by cisplatin and etoposide
Study: 3235816
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg DZ MM i.v. + placebo i.m.
Study: 3235816
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg DZ i.v. + placebo i.m.
Study: 3235816
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg DZ MM i.m. + placebo i.v.
Study: 3235816
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg DZ i.m. + placebo i.v.
Study: 24716668
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg selenium-enriched yeast (SelenoPrecise®) daily for 12 months
Study: 24716668
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets daily for 12 months
Study: 18398972
Drug: Elevated breast
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated breast milk sodium concentration (> or =13 mmol/L) at 4 months
Study: 14666354
Drug: Triancinolone 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triancinolone 10 mg/ml intralesional injection
Study: 14666354
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution 0.9% injection (placebo)
Study: 7943838
Drug: Epidural bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural bupivacaine 0.75% (6-8 ml)
Study: 7943838
Drug: Intravenous bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bupivacaine (1.2 mg.min-1)
Study: 7943838
Drug: Epidural saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural saline (6-8 ml)
Study: 3036980
Drug: Topical drops
Normalized name: benzyl alcohol 10 % TOPICAL DROPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical drops containing combinations of antibiotics and steroids (including one with an anti-fungal agent)
Study: 31044759
Drug: High-salt diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-salt diet (15.2 g/day) after a low-salt diet (2.9 g/day) for 7 days each
Study: 31044759
Drug: High-salt diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-salt diet (15.2 g/day)
Study: 18097227
Drug: Lopinavir/ritonavir (LPV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir (LPV/r) 300/75 mg/m twice daily plus two nucleoside reverse transcriptase inhibitors
Study: 18097227
Drug: Lopinavir/ritonavir (LPV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir (LPV/r) 300/75 mg/m twice daily
Study: 16882678
Drug: Oral CoQ(10)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral CoQ(10) (100 mg tid)
Study: 14714358
Drug: Jiangya Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jiangya Capsule (JYC)
Study: 10813709
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy consisting of intraarterial cisplatin infusion (2 mg/kg every 8 weeks) and systemic interferon-alpha (3 million IU/m2 subcutaneously 3 times a week)
Study: 10813709
Drug: Intraarterial cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraarterial cisplatin infusion (2 mg/kg every 8 weeks)
Study: 10813709
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha
Study: 8782256
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of neomycin, polymyxin B, and dexamethasone
Study: 1738550
Drug: Vestibular suppressant
Normalized name: Buckley's Cough Suppressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vestibular suppressant medication
Study: 30572991
Drug: Non-intervention (insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-intervention (insulin treatment only)
Study: 21073054
Drug: DEC (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEC (300 mg) + Doxycycline (200 mg)
Study: 21073054
Drug: DEC (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEC (300 mg) + Placebo
Study: 28002105
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment with ingenol mebutate gel, 0.015% after 3 weeks
Study: 28002105
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment with vehicle gel after 3 weeks
Study: 21181475
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel (100 mg/m², 1-hour infusion, weekly for 6 weeks)
Study: 15149512
Drug: Vitamin B12
Normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B12 cream applied twice daily for 8 weeks
Study: 15149512
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied twice daily for 8 weeks
Study: 15149512
Drug: Vitamin B12
Normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B12 cream
Study: 9048527
Drug: Sodium dodecyl
Normalized name: Sodium dodecyl sulfate
DrugBank: Sodium lauryl sulfate (DB00815)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting
Study: 8392210
Drug: Isoprenaline (beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoprenaline (beta 1, beta 2, and beta 3-agonist)
Study: 8392210
Drug: Nadolol 20
Normalized name: nadolol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol 20 mg (beta 1/beta 2 antagonist)
Study: 8392210
Drug: Nadolol 5
Normalized name: bendroflumethiazide-nadolol 5 mg-40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol 5 mg (beta 1/beta 2 antagonist)
Study: 8392210
Drug: Atenolol 25
Normalized name: atenolol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 25 mg (beta 1 antagonist)
Study: 2881423
Drug: Lower-dose alfentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-dose alfentanil groups
Study: 24296871
Drug: Allopurinol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (200 mg/day) for 3 months
Study: 18613385
Drug: Haemopressin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemopressin (1 mg tri‐glycyl‐lysin‐vasopressin acetate, 2mg i.v. immediately followed by 1 mg i.v. q4h for 5 days)
Study: 18613385
Drug: Glypressin (2mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glypressin (2mg i.v. immediately followed by 1 mg i.v. q4h for 5 days)
Study: 16636120
Drug: Once-weekly (OW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly (OW) alendronate 70 mg
Study: 16636120
Drug: Once-weekly (OW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly (OW) risedronate 35 mg
Study: 8827792
Drug: Doxapram (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxapram (0.5 mg/kg)
Study: 1426825
Drug: Acamprosate (666
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acamprosate (666 mg, 2 tablets)
Study: 20007794
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of acetaminophen 500 mg and ibuprofen 150 mg per tablet (Maxigesic)
Study: 20007794
Drug: Acetaminophen 500
Normalized name: acetaminophen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 500 mg per tablet alone
Study: 20007794
Drug: Ibuprofen 150
Normalized name: Ibuprofen 150 mg and paracetamol 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 150 mg per tablet alone
Study: 12182272
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg fluoxetine per day
Study: 12182272
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg fluoxetine per day
Study: 10190822
Drug: Glatiramer acetate,
Normalized name: Glatiramer Acetate, 20 mg/mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glatiramer acetate, 20 mg/d
Study: 8846544
Drug: Anti-TNF alpha
Normalized name: anti-interleukin-1.alpha. immunoglobulin G rabbit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF alpha monoclonal antibodies (mabs)
Study: 8846544
Drug: Anti-T cell
Normalized name: Anti-T-lymphocyte immune globulin, rabbit
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-T cell therapies
Study: 2178965
Drug: Theophylline (individually
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (individually titrated dose)
Study: 28402454
Drug: Adalimumab (ADA)
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab (ADA) 160-80-40 mg subcutaneously
Study: 28402454
Drug: Azathioprine (AZA)
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine (AZA) 2.5 mg/kg/day
Study: 26506378
Drug: Gel-Acid (96
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel-Acid (96 kcal whey protein gel)
Study: 26506378
Drug: Gel-Heated (96
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel-Heated (96 kcal whey protein gel)
Study: 23936977
Drug: Intramuscular depot
Normalized name: Primoteston Depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular depot medroxyprogesterone acetate (DMPA) therapy
Study: 23936977
Drug: Severe pain
Normalized name: Orajel Severe Pain Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severe pain prior to treatment
Study: 21299465
Drug: Pamidronate (60‐90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (60‐90 mg once a month for 1 year)
Study: 20439555
Drug: Iron-fortified pandesal
Normalized name: INFANT FORMULA SMA IRON FORTIFIED CONC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-fortified pandesal (hydrogen-reduced iron at 80 mg/kg, electrolytic iron at 80 mg/kg, or ferrous fumarate at 40 mg/kg)
Study: 20439555
Drug: VA-fortified pandesal
Approvals — FDA: no, EMA: no, PMDA: no
Description: VA-fortified pandesal (at 490 RE/100 g)
Study: 17194963
Drug: Estrogen therapy
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen therapy (ET) for 8 weeks
Study: 9740926
Drug: Brompheniramine 8
Normalized name: brompheniramine 8 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brompheniramine 8 mg
Study: 3395665
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg oral dose of terodiline (Mictrol)
Study: 3395665
Drug: Deuterated drug
Normalized name: Deuterated water
DrugBank: Deuterium oxide (DB19251)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deuterated drug as a covariate
Study: 27641967
Drug: Sitagliptin (50-100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin (50-100mg daily)
Study: 25305273
Drug: Phytosterols intake
Normalized name: phytosterols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytosterols intake (average 296 mg/d)
Study: 19455117
Drug: Extracorporeal albumin
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extracorporeal albumin dialysis (ECAD) plus standard medical therapy
Study: 19455117
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy only
Study: 16932229
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy plus NMBAs (n = 18)
Study: 16932229
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy plus placebo (n = 18)
Study: 15384020
Drug: DMSA, 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMSA, 2.5 mg/kg/d for 8 weeks
Study: 11566047
Drug: 50 microg
Normalized name: Digoxin 250 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 microg GHRH administered as a single intravenous bolus
Study: 11566047
Drug: 10 microg
Normalized name: Estradiol 10 microgram vaginal tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 microg GHRH administered as five repetitive boluses within 1 h
Study: 9740479
Drug: Clonidine (transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (transdermal patch)
Study: 8092427
Drug: Amoxicillin (AX)
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin (AX)
Study: 8092427
Drug: Penicillin G
Normalized name: penicillin G
DrugBank: Benzylpenicillin (DB01053)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin G (PG)
Study: 3345614
Drug: Placebo gels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gels (various pH levels)
Study: 30177674
Drug: Spinal ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal ropivacaine (7-15 mg) in Group S (BMI <25)
Study: 30177674
Drug: Spinal ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal ropivacaine (7-15 mg) in Group M (25 ≤ BMI <30)
Study: 30177674
Drug: Spinal ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal ropivacaine (7-15 mg) in Group L (BMI ≥30)
Study: 27102553
Drug: EPO +
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EPO + TXA (10,000 IU EPO daily subcutaneous injections on preoperative days 1-4 and postoperative days 1-3; 15 mg/kg TXA 10 min prior to incision)
Study: 27102553
Drug: TXA (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA (15 mg/kg TXA 10 min prior to incision)
Study: 26423182
Drug: Aripiprazole (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (target dose 10 mg [maximum 15 mg] daily) for 12 weeks
Study: 2744633
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) 500 mg
Study: 2744633
Drug: Choline magnesium
Normalized name: Choline Magnesium Trisalicylate
DrugBank: Choline (DB00122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Choline magnesium trisalicylate (CMT) 500 mg
Study: 736748
Drug: Predicted cancer
Normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Predicted cancer chemotherapy
Study: 736748
Drug: Non-predicted or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-predicted or no surgical adjuvant chemotherapy
Study: 29189311
Drug: Gabapentin 400
Normalized name: gabapentin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 400 mg
Study: 29943522
Drug: Gabapentin 800
Normalized name: gabapentin 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 800 mg
Study: 29189311
Drug: Gabapentin 400
Normalized name: gabapentin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 400 mg, 800 mg, 1200 mg
Study: 25958769
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus brief self-hypnosis training (two × 90-minute groups at around 32 and 35 weeks' gestation; daily audio self-hypnosis CD)
Study: 20652703
Drug: Tanespimycin suspension
Normalized name: Tanespimycin
DrugBank: Tanespimycin (DB05134)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanespimycin suspension for injection
Study: 20652703
Drug: Tanespimycin injection
Normalized name: Tanespimycin
DrugBank: Tanespimycin (DB05134)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanespimycin injection (Cremophor-based formulation)
Study: 20652703
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment with tanespimycin (both formulations)
Study: 17076973
Drug: Mebendazole 200
Normalized name: mebendazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebendazole 200 mg three times for 1 day
Study: 17076973
Drug: Tinidazole 50
Normalized name: tinidazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole 50 mg/kg in a single dose
Study: 11718213
Drug: GM-CSF for
Normalized name: axatilimab-csfr
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF for 3 days, five days prior to chemotherapy
Study: 9109740
Drug: Physostigmine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine (30 mg transdermal patch, releasing about 6 mg over 24 hours)
Study: 7959241
Drug: ESWL with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESWL with adjuvant bile acid treatment
Study: 7959241
Drug: Bile salt
Normalized name: Bile salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bile salt treatment
Study: 24850228
Drug: Olanzapine long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine long-acting injection (LAI) 45-405 mg every 2-4 weeks
Study: 22408034
Drug: Celecoxib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (200 mg twice daily for 3 months)
Study: 16509835
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 mg each morning)
Study: 12623986
Drug: Calcineurin inhibitor-free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcineurin inhibitor-free regimen
Study: 8198628
Drug: Nylestriol 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nylestriol 2 mg/2 wk
Study: 8198628
Drug: Nylestriol 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nylestriol 1 mg/2 wk
Study: 3085844
Drug: Supine position
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supine position with bumetanide 1 mg intravenously
Study: 3085844
Drug: Upright position
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upright position with bumetanide 1 mg intravenously
Study: 31906925
Drug: Oral information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral information session
Study: 31906925
Drug: Pamphlet and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamphlet and oral information session
Study: 24905063
Drug: Estradiol and
Normalized name: Estradiol and Norgestimate Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol and progestin therapy